Safety and efficacy of Philips’ Stellarex .035 low-dose drug-coated balloon demonstrated in clinical trials at three years May 29, 2019 Stellarex is the only low-dose [1] drug-coated balloon (DCB) to demonstrate a significant treatment effect and high safety profile through 3 years ILLUMENATE Pivotal trial showcases...

Philips launches new IntraSight interventional applications platform to seamlessly integrate intravascular imaging and physiology applications for image-guided procedures   May 20, 2019  Integrating best-in-class physiology, imaging and co-registration tools across the interventional lab workflow supports physicians in providing cardiac and peripheral vascular patients...

Philips and Vietnamese Hong Duc General Hospital sign multi-year strategic partnership agreement 11 April 2019 Philips to provide turnkey hospital solution to newly-built Hong Duc General Hospital II, including the latest medical imaging and healthcare IT solutions as well as design,...

DEFINE PCI study finds treatable cause for significant rates of residual ischemia in coronary stent patients March 17, 2019 Nearly one in four patients in the study treated with standard of care percutaneous coronary intervention (PCI) had residual ischemia after coronary stent implantation intended to...

Philips showcases unique augmented reality concept for image-guided minimally invasive therapies developed with Microsoft February 24, 2019 Companies collaborate to combine Philips’ industry-leading Azurion image-guided therapy platform with Microsoft HoloLens 2 mixed reality computing platform as a concept...